Tonic Bioventures
Tonic Bioventures is an early-stage venture capital fund founded in 2020 and based in Glen Burnie, Maryland, that invests in life sciences companies across therapeutics, diagnostics, and devices. The firm is led by co-founders and general partners Regina Leung and Jim Sergi.
- Company typePrivate
- Founded2020
- HeadquartersGlen Burnie, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Tonic Bioventures does
Tonic Bioventures is an early-stage venture capital fund founded in 2020 and headquartered in Glen Burnie, Maryland, that invests across life sciences sub-sectors including therapeutics, diagnostics, and devices. The firm is led by two co-founders, Regina Leung and Jim Sergi, who both serve as general partners, suggesting a partnership-driven model typical of boutique specialist funds. Public information is sparse: the firm's own website returned a CAPTCHA/verification page rather than substantive content during data aggregation, and the only disclosed capital event surfaced is a 2022 funding round listing ExCapsa Group as an investor with a $0 disclosed value.
The firm's business model follows conventional venture fund economics: capital is raised from limited partners, deployed into early-stage life sciences companies, and the firm earns revenue through management fees (typically a percentage of committed capital) and carried interest on successful exits. With 11-50 employees, the organization is sized for a small specialist fund rather than a scaled multi-strategy platform. No portfolio companies, AUM figures, fund vintages, or LP roster are disclosed in the available data, which limits assessment of fund maturity, deployment pace, and underlying revenue drivers.
Tonic Bioventures firmographics
Firmographics- Name
- Tonic Bioventures
- Website
- https://tonicbioventures.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Tonic Bioventures is an early-stage venture capital fund founded in 2020 and based in Glen Burnie, Maryland, that invests in life sciences companies across therapeutics, diagnostics, and devices. The firm is led by co-founders and general partners Regina Leung and Jim Sergi.
- Ownership category
- akta.pro rank
Tonic Bioventures industry classification
Industry- Product category
- Venture Capital (Life Sciences)
- SIC
- Investment Advice (6282)
- akta.pro primary industry
- Early-Stage Venture Capital (Series A/B) (FSANAAAB)
- akta.pro secondary industry
- Micro-VC & Angel Funds (FSANAAAI)
Keywords
Where Tonic Bioventures is headquartered
LocationHeadquarters
- HQ city
- Glen Burnie
- HQ country
- United States
- HQ region
- North America
Markets served
Tonic Bioventures business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales
Tonic Bioventures product offering
Product offeringCore offering
Tonic Bioventures is an early-stage venture fund that invests in life sciences companies across therapeutics, diagnostics, and medical devices. The firm deploys capital into founding-stage and early-stage life sciences startups, supporting entrepreneurs developing new treatments, diagnostic tools, and device technologies.
Differentiator
Problem solved
Functional benefit
Products and services
- Early-stage life sciences venture fund
Companies that use Tonic Bioventures
Customer profileIdeal customer profiles1 record
Tonic Bioventures technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Tonic Bioventures partnerships and signals
Strategic signalRecent moves2 records
Tonic Bioventures competitors and assessment
Company assessmentDirect peers
- ARCH Venture Partners: ARCH is one of the largest and most established early-stage life-sciences venture firms, investing across therapeutics, diagnostics, and medical devices from seed through Series A — directly comparable in mandate and stage focus to Tonic Bioventures.
- Atlas Venture: Atlas Venture is a dedicated early-stage life-sciences fund that builds biotech companies from inception, with a focus on therapeutics. Its early-stage, biotech-only mandate closely mirrors Tonic's stated focus on therapeutics, diagnostics, and devices.
- 5AM Ventures: 5AM Ventures is an early-stage life-sciences investor focused on creating and building therapeutics and platform companies. Its stage focus and sector concentration make it a strong direct comparable to Tonic Bioventures.
- Versant Ventures: Versant is a healthcare-focused venture firm investing across therapeutics, medical devices, and diagnostics at the early and growth stages, with a portfolio approach very similar to Tonic's stated investment scope.
- Frazier Life Sciences: Frazier Life Sciences invests exclusively in therapeutics and related life-sciences companies across all stages, including seed and Series A, making it a direct sector and stage comparable to Tonic Bioventures.
- Lux Capital: Lux Capital invests across frontier science and technology, with a substantial allocation to life sciences including therapeutics, diagnostics, and bio-platform companies, overlapping meaningfully with Tonic's investment scope.
- Section 32: Section 32 is a venture fund founded by a former Google Ventures general partner that invests in biotech, healthcare, and techbio at early stages. Its life-sciences orientation and early-stage mandate align with Tonic's focus.
Broad incumbents
- New Enterprise Associates (NEA): NEA is a large, multi-stage venture firm with a significant life-sciences practice that invests across therapeutics, diagnostics, and devices. As a much larger incumbent, it is a relevant broad comparable but operates at materially different scale than Tonic.
- Flagship Pioneering: Flagship Pioneering is a large bioplatform venture firm that creates and funds therapeutics and platform biotech companies. As a much larger and better-known incumbent, it is a relevant broad sector comparable to Tonic's therapeutics and diagnostics focus.
- Andreessen Horowitz Bio: Andreessen Horowitz's Bio fund invests across therapeutics, diagnostics, and digital health at the early stages. As a well-capitalized incumbent with a dedicated life-sciences practice, it competes for the same early-stage deal flow as Tonic Bioventures.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat2 records
Key risks5 records
Key highlights5 records
Customer concentration
Tonic Bioventures social profiles
Digital presenceTonic Bioventures financial estimates
Financial estimateRevenue estimate
Valuation estimate
Tonic Bioventures leadership team
Management profileNumber of profiles
Profiles2 records
Tonic Bioventures funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Tonic Bioventures M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Tonic Bioventures
What does Tonic Bioventures do?
Tonic Bioventures is an early-stage venture fund that invests in life sciences companies across therapeutics, diagnostics, and medical devices. The firm deploys capital into founding-stage and early-stage life sciences startups, supporting entrepreneurs developing new treatments, diagnostic tools, and device technologies.
When was Tonic Bioventures founded?
Tonic Bioventures was founded in 2020. It employs 11 to 50 people.
Where is Tonic Bioventures based?
Tonic Bioventures is headquartered in Glen Burnie, United States, in the North America region.
Who are Tonic Bioventures's main competitors?
Direct peers on record are ARCH Venture Partners, Atlas Venture, 5AM Ventures, Versant Ventures, Frazier Life Sciences, Lux Capital and Section 32. Broad incumbents are New Enterprise Associates (NEA), Flagship Pioneering and Andreessen Horowitz Bio.
Does Tonic Bioventures have an API?
No public API is recorded for Tonic Bioventures.
What industry is Tonic Bioventures in?
Tonic Bioventures's product category is Venture Capital (Life Sciences). Its primary akta.pro industry code is FSANAAAB, Early-Stage Venture Capital (Series A/B), with a secondary code of FSANAAAI, Micro-VC & Angel Funds. Its SIC code is 6282.